Search clinical trials for: Pneumococcal infection

Total 57082 results

MCM Vaccines B.V.
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)

Virus Diseases | Bacterial Infections
Merck Sharp & Dohme LLC

Completed

A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003)

Pneumococcal Infections
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)

Pneumococcal Infections
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-005)

Pneumococcal Infections
MCM Vaccines B.V.
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)

Virus Diseases | Bacterial Infections
MCM Vaccines B.V.

Completed

Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011)

Virus Diseases | Bacterial Infections | Neisseria Meningitidis
Prof. Elizabeth Miller

Completed

Evaluating Vaccine Responses in Healthy Infants Receiving Their Routine Primary Immunisation According to the Accelerated United Kingdom Schedule at 2, 3 and 4 Months (P13UK)

Streptococcus Pneumoniae

United Kingdom
Public Health England
Institute of Child Health; National Institute of Biological Standards and Control

Completed

Study to Evaluate the Immune Response of United Kingdom (UK) Infants Receiving DTaP/Hib/IPV, Meningococcal C Conjugate and Pneumococcal Conjugate Vaccines, Antibody Persistence and Responses to Booster Doses in the Second Year of Life (Sched2)

Pneumococcal Infections | Meningococcal Infections

United Kingdom
Public Health England

Completed

A Study to Assess the Impact of Pneumococcal Conjugate Vaccination Programme on the Carriage of Pneumococci (Pneucast)

Pneumococcal Disease

United Kingdom
NICHD Neonatal Research Network
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Completed

Immunogenicity of PCV-7 Vaccine in VLBW Infants (PCV-7)

Pneumococcal Infections | Streptococcus Pneumoniae | Infant, Small for Gestational Age | Infant, Premature | Infant, Low Birth Weight | Infant, Newborn

United States
Merck Sharp & Dohme LLC

Completed

Safety and Tolerability Study for the Pneumococcal Conjugate Vaccine V114 Versus Prevnar™ (V114-001)

Pneumococcal Infections
Virginia Commonwealth University

Completed

Pharmacist Impact on Pneumococcal Polysaccharide Vaccination Rates in Patients With Diabetes in a Supermarket Pharmacy Chain

Pneumococcal Pneumonia

United States
MCM Vaccines B.V.
Merck Sharp & Dohme LLC; Sanofi Pasteur, a Sanofi Company

Completed

Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010)

Virus Diseases | Bacterial Infections | Neisseria Meningitidis
Michael A. Thompson, MD, PhD
Vince Lombardi Cancer Clinic

Completed

Study of the Immune Response After Vaccination in Multiple Myeloma Patients

Multiple Myeloma | Myeloma, Multiple | Myeloma-Multiple

United States
GlaxoSmithKline

Terminated

Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children

Influenza

Norway
Korea University Guro Hospital

Completed

Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine Among HIV-infected Adults

HIV/AIDS | Streptococcal Pneumonia
Duke University
Centers for Disease Control and Prevention; Kaiser Permanente

Completed

Fever After Simultaneous Versus Sequential Vaccination in Young Children

Fever | Febrile Seizure | Fever After Vaccination

United States
Kameda Medical Center
Merck Sharp & Dohme LLC; PPD; Osaka University

Completed

The Immunogenicity of Simultaneous Administration of Quadrivalent Influenza Vaccine and 23-valent Pneumococcal Vaccine

Influenza | Pneumococcal Pneumonia

Japan
GlaxoSmithKline

Completed

Prophylactic Antipyretic Treatment in Children Receiving Booster Dose of Pneumococcal Conjugate Vaccine GSK1024850A

Infections, Streptococcal

Czechia
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine

Infections, Streptococcal

Finland
GlaxoSmithKline

Completed

Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same Vaccines

Infections, Streptococcal

Poland, Philippines
Pfizer

Completed

Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants

Healthy Subjects

Japan
GlaxoSmithKline

Completed

Assess Reacto- and Immunogenicity of Pneumococcal Conjugate Vaccine When Given as Booster or a 2 Dose Catch up Schedule

Infections, Streptococcal

Chile
Pfizer

Completed

A Study to Assess the Antibody Response of Healthy Chinese Children Who Have Been Vaccinated Previously With 4-doses of Prevenar (a Pneumococcal Vaccine) as Babies and Toddlers

Pneumococcal Disease

China
GlaxoSmithKline

Completed

Study to Evaluate the Safety and Immunogenicity of a 10-valent Pneumococcal Conjugate Vaccine in Preterm Infants

Infections, Streptococcal

Spain, Greece
GlaxoSmithKline

Completed

Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A and of Unprimed Children in Mali

Infections, Streptococcal

Mali
Merck Sharp & Dohme LLC

Completed

The Safety, Tolerability, and Immunogenicity Profiles of a Single Dose of V114, PNEUMOVAX® 23, or PREVNAR 13® in Adults 50 Years of Age or Older (V114-002)

Pneumococcal Infections
Region Skane
Lund University

Completed

Effects of Different Antirheumatic Treatments of Arthritis on Antibody Response Following Vaccination Using Prevenar® (PVA)

Rheumatoid Arthritis | Spondylarthropathy

Sweden
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine

Infections, Streptococcal

Poland, Philippines
Pfizer
Kaiser Permanente

Completed

Study Estimating the Impact of Prevnar 13™ (13vPnC) on Invasive Pneumococcal Disease

Invasive Pneumococcal Disease

United States
LimmaTech Biologics AG

Completed

Phase I to Test a New Pneumococcal Vaccine

Pneumonia, Bacterial | Pneumococcal Pneumonia

Germany
Pfizer

Completed

Serotype Distribution of Chest X-ray Confirmed Pneumococcal Community Acquired Pneumonia in the Adult Population in Greece, Over 1 Year. (B1851065)

Pneumococcal Disease

Greece
Merck Sharp & Dohme LLC
MCM Vaccines B.V.

Completed

Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)

Virus Diseases | Bacterial Infections
Merck Sharp & Dohme LLC
MCM Vaccines B.V.

Completed

A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)

Virus Diseases | Bacterial Infections
Merck Sharp & Dohme LLC

Completed

Revaccination With PNEUMOVAX™ 23 in Older Japanese Adults (V110-902)

Pneumococcal Infection
Merck Sharp & Dohme LLC

Completed

A Phase III Clinical Trial to Study the Safety and Immunogenicity of Pneumovax™ 23 (V110) in Participants From the Russian Population (V110-018)

Pneumococcal Disease
University of Oxford

Completed

A Study of the Interaction Between BCG And MenC Immunisation: BAM (BAM)

Immune Response | BCG Infection | Reaction - Vaccine

United Kingdom
GlaxoSmithKline

Completed

Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age

Measles | Rubella | Mumps | Varicella

United States
Novartis Vaccines

Completed

Immunogenicity and Safety of MenACWY in Infants (6 & 12 Months)

Meningococcal Meningitis

Canada
Emory University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Systems Biology of PNEUMOVAX®23 and PREVNAR 13®

Pneumococcal Infection

United States
GlaxoSmithKline

Completed

An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children

Influenza

Spain, Poland, Philippines, Thailand, Belgium, United Kingdom, Czechia, Bangladesh, Dominican Republic, Honduras, Lebanon, Turkey, India
GlaxoSmithKline

Completed

Booster Vaccination Study With a Pneumococcal Vaccine in Children Primed With the Same Vaccine

Infections, Streptococcal

Korea, Republic of
GlaxoSmithKline

Completed

Long-term Follow-up Study of Children Previously Primed With GSK Pneumococcal Vaccine (GSK1024850A) and of Unprimed Children

Infections, Streptococcal

Czechia
GlaxoSmithKline

Completed

Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A and of Unprimed Children in Nigeria

Infections, Streptococcal

Nigeria
GlaxoSmithKline

Completed

Immunological Persistence After Priming With GSK1024850A Vaccine and Safety& Immunogenicity After Booster Dose

Infections, Streptococcal

Singapore
GlaxoSmithKline

Completed

Booster and Catch-up Vaccination With Vaccine GSK1024850A

Infections, Streptococcal

India
University of Florida
Colgate Palmolive

Completed

Periodontal Treatment Response in Type II Diabetic Patients

Periodontal Disease | Type II Diabetes

United States
GlaxoSmithKline

Completed

Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age

Neisseria Meningitidis | Haemophilus Influenzae Type b

United States
Pfizer

Completed

A Phase 1, Randomized, Controlled, Observer-blinded Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Healthy Adults Aged 18 to 49 Years

Pneumococcal Infections

United States
Pfizer

Completed

A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Subjects

Pneumococcal Infection

China

3

Subscribe